Keylika

Coral integrates molecular, functional, and clinical factors to create new clinical laboratory tests that predict optimal treatments for autoimmune diseases. We have also identified a unique subpopulation of patients who do not respond to current therapies and are working towards addressing this unmet medical need.

shared extracted concept terms: unmet, medical, need; shared product terms: molecular, clinical, treatment, unmet; shared product theme: health and clinical care; shared affiliation: Y Combinator

What we do? We develop digital therapeutics to address unmet medical needs in hematology and oncology. How it works? First we build networks of doctors and patients designed to track, predict and prevent disease. Second, we validate the safety and efficacy of our interventions in pivotal clinical studies to obtain regulatory clearance (SaMD). Finally, we aim to commercialize our products as prescription digital therapeutics (DTx). Where are we now? Today, we are the standard in digital hematolog

shared extracted concepts: unmet medical needs; shared product terms: develop, unmet, medical, need; shared product theme: health and clinical care; shared affiliation: Y Combinator

Sigma Genetics develops devices that can deliver DNA, RNA, and other charged molecules into cells by using magnetic fields. When compared to conventional electroporation, this technique has several key advantages, which include: the absence of arcing, the ability to scale, and the benefit of being non-invasive for in vivo applications. This platform technology can be applied to a wide range of applications- cell therapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and cosmetic

shared extracted concept terms: biopharma; shared product terms: biopharma, develop, drug, delivery; shared affiliation: Y Combinator

CCG.ai exist to ensure that each patient has the right drug, at the right time, to beat their cancer. ‍ We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance. We are expanding our team in Cambridge,

shared extracted concept terms: treatment; shared product terms: exist, drug, develop, treatment; shared product theme: health and clinical care; shared affiliation: Y Combinator

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affe

shared product terms: develop, small, molecule, drug; same category: Healthcare; shared affiliation: Y Combinator

Eight medical is a platform connecting emergency medical resources to users in need in 10 mins

shared extracted concept terms: need, medical; shared product terms: medical, need; shared product theme: health and clinical care; same category: Healthcare